Merus Stock Forecast, Price & News

-0.23 (-1.00 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $22.83
50-Day Range
MA: $22.28
52-Week Range
Now: $22.83
Volume91,654 shs
Average Volume178,380 shs
Market Capitalization$870.44 million
P/E RatioN/A
Dividend YieldN/A
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Merus logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MRUS
Year FoundedN/A



Sales & Book Value

Annual Sales$31.13 million
Book Value$5.61 per share


Net Income$-55,150,000.00
Net Margins-295.98%


Market Cap$870.44 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


Merus (NASDAQ:MRUS) Shares Gap Up to $21.59
April 5, 2021 |
-$0.11 EPS Expected for Merus (NASDAQ:MRUS) This Quarter
April 3, 2021 |
Merus (NASDAQ:MRUS) Shares Gap Down to $19.50
March 30, 2021 |
Merus (NASDAQ:MRUS) PT Raised to $30.00 at HC Wainwright
March 23, 2021 |
See More Headlines


Overall MarketRank

1.61 out of 5 stars

Medical Sector

376th out of 2,016 stocks

Pharmaceutical Preparations Industry

174th out of 771 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
-0.23 (-1.00 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Merus (NASDAQ:MRUS) Frequently Asked Questions

Is Merus a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus
or view top-rated stocks.

What stocks does MarketBeat like better than Merus?

Wall Street analysts have given Merus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Merus

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) posted its quarterly earnings data on Monday, March, 15th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.53. Merus had a negative net margin of 295.98% and a negative trailing twelve-month return on equity of 78.70%.
View Merus' earnings history

How has Merus' stock price been impacted by Coronavirus?

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has increased by 57.0% and is now trading at $22.83.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MRUS?

5 Wall Street analysts have issued 1-year price objectives for Merus' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Merus' stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Merus
or view top-rated stocks among Wall Street analysts.

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Sven Ante Lundberg, CEO, Pres, Principal Financial Officer & Exec. Director (Age 58, Pay $33.24k)
  • Mr. Hui Liu, Chief Bus. Officer, Exec. VP & Head of Merus U.S. (Age 54, Pay $546.03k)
  • Dr. Hennie Hoogenboom, Co-Founder and Scientific Advisor
  • Mr. Cornelis Adriaan de Kruif Ph.D., CTO & Sr. VP (Age 57)
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. Peter B. Silverman J.D., Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal (Age 43)
  • Mr. Alexander Berthold Hendrik Bakker Ph.D., Chief Devel. Officer & Sr. VP (Age 54)
  • Dr. Andrew Joe M.D., Chief Medical Officer (Age 55)
  • Dr. Ellen Broug, Exec. Director of IP & Sec.
  • Ms. Anne Noordzij, Sec.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $22.83.

How much money does Merus make?

Merus has a market capitalization of $870.44 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

How many employees does Merus have?

Merus employs 93 workers across the globe.

What is Merus' official website?

The official website for Merus is

Where are Merus' headquarters?

Merus is headquartered at YALELAAN 62, UTRECHT P7, 3584 CM.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.